The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Articles|April 30, 2019
Fenova Renal Research Adds to Roster
Advertisement
Frenova Renal Research, a division of Fresenius Medical Care North America (FMCNA) and the contract clinical research services provider dedicated exclusively to renal research, has added an additional location to its roster of manged clinical research sites. The new capacity will enhance Frenova's ability to help clinical research sponsors enroll patients rapidly and streamline clinical trials.
"We look forward to managing this site and working alongside our new partner investigators. Increasing our network of investigators and pool of patients allows our clients to significantly accelerate their clinical trials designed to ultimately better the lives of those living with renal disease," said Kurt Mussina, vice president, FMCNA, and general manager, Frenova Renal Research. "Between 2016 and 2018, we reduced the time from clinical trial agreement to first-patient-first-visit by over 80 percent among the sites we manage."
Frenova's approach to site management reduces administrative burdens, thereby compressing timelines. This provides investigators at sites managed by Frenova the opportunity to enroll patients sooner and with greater efficiency than they would otherwise.
The Las Vegas site of Nevada Kidney Disease and Hypertension Centers contributes 24 physicians, 2,000 ESRD patients, and 15,000 CKD patients to the program.
For more information visit
Advertisement
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
5